Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
1.
J Clin Immunol ; 44(2): 50, 2024 Jan 17.
Article in English | MEDLINE | ID: mdl-38231281

ABSTRACT

Several genetic and immunological risk factors for severe COVID-19 have been identified, with monogenic conditions relating to 13 genes of type I interferon (IFN) immunity proposed to explain 4.8% of critical cases. However, previous cohorts have been clinically heterogeneous and were not subjected to thorough genetic and immunological analyses. We therefore aimed to systematically investigate the prevalence of rare genetic variants causing inborn errors of immunity (IEI) and functionally interrogate the type I IFN pathway in young adults that suffered from critical COVID-19 yet lacked comorbidities. We selected and clinically characterized a cohort of 38 previously healthy individuals under 50 years of age who were treated in intensive care units due to critical COVID-19. Blood samples were collected after convalescence. Two patients had IFN-α autoantibodies. Genome sequencing revealed very rare variants in the type I IFN pathway in 31.6% of the patients, which was similar to controls. Analyses of cryopreserved leukocytes did not indicate any defect in plasmacytoid dendritic cell sensing of TLR7 and TLR9 agonists in patients carrying variants in these pathways. However, lymphocyte STAT phosphorylation and protein upregulation upon IFN-α stimulation revealed three possible cases of impaired type I IFN signaling in carriers of rare variants. Together, our results suggest a strategy of functional screening followed by genome analyses and biochemical validation to uncover undiagnosed causes of critical COVID-19.


Subject(s)
COVID-19 , Interferon Type I , Humans , Young Adult , COVID-19/genetics , Interferon-alpha , Signal Transduction , Autoantibodies
2.
Eur Rev Aging Phys Act ; 17: 15, 2020.
Article in English | MEDLINE | ID: mdl-32973961

ABSTRACT

BACKGROUND & AIMS: Evidence suggests that targeted exercise is important for people living with dementia. The aim of this review was to collect and synthesize evidence on the known barriers and facilitators to adherence to walking group exercise of older people living with dementia in the community. METHODS: We have searched appropriate electronic databases between January 1990 until September 2019, in any language. Additionally, we searched trial registries (clinicaltrial.gov and WHO ICTRP) for ongoing studies. We included all study designs. Studies were excluded when participants were either healthy older people or people suffering from dementia but living in residential care. Narrative synthesis was used. FINDINGS: 10 papers met the inclusion criteria. The narrative analysis focused on barriers, facilitators, and adherence. All studies reported on barriers and facilitators. Barriers included: bio-medical reasons (including mental wellbeing and physical ability); relationship dynamics; and socio-economic reasons and environmental issues. Facilitators included: bio-medical benefits & benefits related to physical ability; staff, group relationship dynamics and social aspect of walking group; environmental issues and individual tailoring; and participants perceptions about the walks & the program. Most studies did not provide data about adherence or attendance; where reported, adherence ranged from 47 to 89%. CONCLUSIONS: This systematic review of literature has highlighted known barriers and facilitators to adherence to walking groups type of exercise for people living with dementia in community. Carers' willingness to engage, their circumstances, perspectives and previous experiences of exercise seem to play a key role in facilitating adherence but there is little research that explores these. Also, the design, location and organisation of walking groups facilitate adherence. This reflects the need for such activities to be part of a wider 'program of care', tailored to the needs of the individual, flexible and convenient. Knowledgeable and well-trained instructors or healthcare professionals are recommended as group exercise leaders.

3.
QJM ; 110(1): 5-7, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27770051
4.
Int J Cardiol ; 134(2): 195-200, 2009 May 15.
Article in English | MEDLINE | ID: mdl-18508139

ABSTRACT

BACKGROUND: Speckle tracking echocardiography (STE) is an angle independent method with high temporal resolution, which offers quantification of regional left ventricular (LV) wall motion. We studied radial and longitudinal LV wall motion by STE in healthy subjects with normal wall motion analysis (WMA) by eye-balling. MATERIALS AND METHODS: Eighteen healthy subjects were studied. We acquired parasternal short and apical long axis projections to determine the basal, mid and apical radial and longitudinal functions. At each level we measured; (I) radial and longitudinal peak displacement and displacement at aortic valve closure (AVC) and (II) the time interval from the Q-wave to the AVC and peak displacement. RESULTS: WMA indicated normal wall motion in all subjects. The mean peak radial displacement varied in different segments (range 3.9-9.8 mm) with highest values in the mid-level (6.9+/-1.5 mm), compared to basal level (5.9+/-1.0 mm, p<0.01) and apical level (5.4+/-1.0 mm, p<0.001). The time from Q-wave to AVC was 393 ms and in 89% of the analysed segments peak radial displacement occurred after AVC, thus mean peak radial displacement occurred 60 ms after AVC. The peak longitudinal amplitude was more synchronous with respect to AVC and with the highest amplitudes found in the two basal segments. CONCLUSIONS: In normal LV function, significant differences in peak displacement exist between segments at various LV levels using STE. In addition, in early diastole, significant discrepancy occurs between radial and longitudinal time of peak displacement, suggesting a shape change. Finally, while radial displacement was highest at mid-cavity level longitudinal displacement was highest at basal level.


Subject(s)
Echocardiography/methods , Echocardiography/standards , Systole , Ventricular Function, Left , Adult , Aged , Aortic Valve/diagnostic imaging , Female , Humans , Male , Middle Aged , Pilot Projects , Reference Values , Reproducibility of Results , Young Adult
5.
BJU Int ; 87(9): 876-81, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11412230

ABSTRACT

OBJECTIVE: To determine some of the genetic alterations involved in the pathogenesis and progression of transitional cell carcinoma of the bladder. Materials and methods In a population-based study, freshly frozen tissue was collected from all patients newly diagnosed with urinary bladder cancer in the Stockholm region during 1995-1996. The prevalence of loss of heterozygosity (LOH) was assessed at seven sites on chromosome 3, analysed in 151 patients, using a fluorescent multiplex polymerase chain reaction based on DNA from the tumour and peripheral blood. RESULTS: LOH was detected in 12.1% (at 3q25-26.2) to 22.1% (at 3p11-12) of the informative cases. Relatively frequent LOH was detected at 3p22-24.2 (21.6%), at 3p14.2 within FHIT (21.5%), and at 3p11-12 (22.1%). Of 151 tumours, 72 (47.7%) showed LOH at one or more loci on chromosome 3. LOH on chromosome 3 was weakly associated with tumour grade (P = 0.095), but not with tumour stage (P = 0.701). However, when the frequency of LOH was analysed individually at each site, the prevalence of LOH at 3p11-12 was closely correlated with higher tumour stage (P = 0.011). Replication errors were detected in only four of 151 (2.6%) tumours. Conclusion These findings suggest that the 3p11-12 locus may involve a putative candidate tumour-suppressor gene which might be associated with bladder tumour invasiveness. The FHIT gene locus showed a relatively high frequency of LOH even in Ta tumours.


Subject(s)
Acid Anhydride Hydrolases , Chromosomes, Human, Pair 3/genetics , Loss of Heterozygosity/genetics , Neoplasm Proteins , Proteins/genetics , Urinary Bladder Neoplasms/genetics , Adult , Aged , Aged, 80 and over , Cohort Studies , Female , Humans , Male , Microsatellite Repeats , Middle Aged , Polymerase Chain Reaction/methods
6.
Clin Cancer Res ; 6(2): 610-5, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10690546

ABSTRACT

Inhibition of the retinoblastoma tumor suppressor gene (RB) is probably important in the pathogenesis of urinary bladder cancer. Little information is available concerning allelic loss on 13q11 to 13q32 and its relation to grade and stage. In a population-based study, freshly frozen tissue was collected from all new cases of urinary bladder cancer in the Stockholm region during 1995-1996. Here we report the occurrence of loss of heterozygosity (LOH) at seven sites in 13q11 to 13q32 as analyzed in 236 cases by a fluorescent multiplex PCR-based on tumor DNA and peripheral blood. For each site, about 30% of the cases were not informative because of homozygosity. Replication errors were detected in 4% (17 cases). LOH was found in 21 (at 13q11-12.1) to 32% (at 13q14.3 in RB) of the informative cases. A correlation was found between the prevalence of LOH at all observed loci and stage and grade, respectively, and it was statistically significant for 13q14.3. LOH at RB was found in Ta as well as grade 1 tumors. Also, a statistically significant correlation was found between the number of loci with LOH at 13q and tumor stage and grade, respectively. Typically an altered RB function is related to the expected clinical course of urinary bladder cancer, but allelic loss including the gene also occurs in low grade and low stage tumors. An altered RB function probably is not necessary for a malignant transformation of urothelial cells. The causal direction of the relation between the quantity of the deleted DNA and tumor aggressiveness is not clear.


Subject(s)
Chromosomes, Human, Pair 13 , Genes, Retinoblastoma , Loss of Heterozygosity , Microsatellite Repeats , Urinary Bladder Neoplasms/genetics , Urinary Bladder Neoplasms/pathology , Alleles , Biopsy , Chromosome Mapping , DNA/blood , Genetic Markers , Humans , Neoplasm Staging , Polymerase Chain Reaction , Urinary Bladder Neoplasms/surgery
8.
Scand J Urol Nephrol Suppl ; 138: 187-91, 1991.
Article in English | MEDLINE | ID: mdl-1785002

ABSTRACT

Sixty patients with Ta and T1 bladder cancer were randomized between treatment with resection only and resection and instillations with either Adriamycin or Mitomycin C. Treatment lasted for one year and patients were evaluated after a mean follow-up of 35 to 47 months if progression had not occurred. Mitomycin C was superior in reducing the recurrence rate. Progressive disease was observed in 17 patients regardless of therapy but in all patients DNA aneuploidy could be identified at a risk factor.


Subject(s)
DNA, Neoplasm/genetics , Doxorubicin/administration & dosage , Mitomycin/administration & dosage , Ploidies , Urinary Bladder Neoplasms/drug therapy , Administration, Intravesical , Combined Modality Therapy , Doxorubicin/adverse effects , Female , Humans , Male , Mitomycin/adverse effects , Neoplasm Recurrence, Local , Prognosis , Urinary Bladder Neoplasms/genetics , Urinary Bladder Neoplasms/pathology , Urinary Bladder Neoplasms/surgery
9.
Acta Oncol ; 29(2): 155-62, 1990.
Article in English | MEDLINE | ID: mdl-2185803

ABSTRACT

In a randomized study of advanced renal cell carcinoma 60 patients were allocated to treatment with either recombinant interferon alpha-2a or medroxyprogesterone acetate. Correlation between the dose of interferon alpha-2a and plasma-concentration indicated linear kinetics. Survival was similar in the two treatment groups. Only one complete and one partial response were seen in the interferon group and only one complete response in the medroxyprogesterone group, indicating a low therapeutic potential of both interferon and medroxyprogesterone. Interferon influenced the serum liver enzyme levels; increased transaminases were seen in 17 patients treated with interferon but in only four patients in the medroxyprogesterone group. Two patients had very high serum liver-enzyme levels concomitant with intolerable tiredness, in both patients the symptoms disappeared and the enzymes normalized after discontinuation of the interferon treatment. Antibodies to interferon developed frequently in patients receiving high dose oligomeric interferon therapy but rarely in patients receiving low dose monomeric interferon treatment.


Subject(s)
Carcinoma, Renal Cell/therapy , Interferon Type I/therapeutic use , Interferon-alpha/therapeutic use , Kidney Neoplasms/therapy , Medroxyprogesterone/therapeutic use , Adult , Aged , Carcinoma, Renal Cell/drug therapy , Carcinoma, Renal Cell/mortality , Carcinoma, Renal Cell/pathology , Female , Humans , Interferon alpha-2 , Interferon-alpha/adverse effects , Interferon-alpha/blood , Kidney Neoplasms/drug therapy , Kidney Neoplasms/mortality , Kidney Neoplasms/pathology , Liver/enzymology , Male , Medroxyprogesterone/adverse effects , Middle Aged , Randomized Controlled Trials as Topic , Recombinant Proteins
10.
Urology ; 32(5): 416-7, 1988 Nov.
Article in English | MEDLINE | ID: mdl-3188305

ABSTRACT

We report on penile ulcus as a complication of self-induced papaverine erections in 2 patients. The ulcers which occurred after inadvertent subcutaneous injection of the drug healed in four to six weeks. The patients resumed papaverine injections without subsequent adverse effects.


Subject(s)
Papaverine/adverse effects , Penile Diseases/chemically induced , Penile Erection , Humans , Injections/adverse effects , Male , Middle Aged , Ulcer/chemically induced
12.
Urol Res ; 15(4): 199-202, 1987.
Article in English | MEDLINE | ID: mdl-3672667

ABSTRACT

Tumors and biopsies from visibly normal urothelium in 36 consecutive patients with transitional cell bladder carcinoma were analysed for histological pathology, DNA ploidy and ABH isoantigens. Tumor isoantigen deletion correlated strongly with malignant histology (p = 0.016) and aneuploidy (p = 0.005). In 4/12 patients with ABH isoantigens present on the tumor, and in 6/8 with isoantigens absent, isoantigen changes were found in normal looking urothelium, usually with normal histology and ploidy. It was concluded that the ABH isoantigen change was an early event in bladder carcinoma.


Subject(s)
ABO Blood-Group System , Carcinoma, Transitional Cell/genetics , DNA/analysis , Isoantigens/analysis , Urinary Bladder Neoplasms/genetics , Urinary Bladder/pathology , Biopsy , Flow Cytometry , Humans
13.
Scand J Urol Nephrol ; 21(2): 125-30, 1987.
Article in English | MEDLINE | ID: mdl-3616504

ABSTRACT

Eighteen patients with transitional cell bladder carcinoma and increasingly abnormal ploidy were assembled to evaluate the relation over time between ploidy and ABH isoantigen deletion. Fifteen patients with diploid recurrent tumors and 16 with aneuploid tumors over time were used as controls. ABH isoantigen deletion at diagnosis was closely related to cancer death, while isoantigen assessments on recurrences gave less prognostic information. Aneuploidy at diagnosis also indicated an adverse prognosis, as did recurrent bladder carcinoma with deteriorating ploidy. Patients with tumors deleted of isoantigen expression at diagnosis but with normal ploidy had as bad a prognosis as patients with deleted tumors and aneuploidy, indicating that isoantigen deletion may occur earlier than ploidy changes.


Subject(s)
Carcinoma, Transitional Cell/immunology , Isoantigens/analysis , Urinary Bladder Neoplasms/immunology , Adult , Aged , Aged, 80 and over , Carcinoma, Transitional Cell/genetics , Carcinoma, Transitional Cell/pathology , DNA, Neoplasm/analysis , Female , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/immunology , Ploidies , Prognosis , Urinary Bladder Neoplasms/genetics , Urinary Bladder Neoplasms/pathology
14.
Cancer ; 58(11): 2428-34, 1986 Dec 01.
Article in English | MEDLINE | ID: mdl-3768837

ABSTRACT

The occurrence and/or deletion of A, B, H isoantigens in cytologic specimens was compared to a number of other clinical parameters commonly used for prediction of prognosis or monitoring of bladder carcinoma. Isoantigens were better preserved by our preparation for cytologic than for histologic specimens. Patients with isoantigen present on urothelial cells were more likely to have small or no visible tumors than large tumors. A strong correlation was found between isoantigen status and cytologic diagnosis (P less than 0.001), but not with ploidy (P = 0.059). For short-term prognosis of recurrence, tumor size appeared to be highly significant, whereas A, B, H isoantigen determinations had no predictive value. Intravesical chemotherapy did not per se influence expression/deletion of isoantigens.


Subject(s)
ABO Blood-Group System/genetics , Urinary Bladder Neoplasms/genetics , Adult , Aged , Female , Flow Cytometry , Humans , Male , Middle Aged , Neoplasm Invasiveness , Neoplasm Staging , Ploidies , Prognosis , Specimen Handling , Urinary Bladder Neoplasms/pathology , Urinary Bladder Neoplasms/therapy
15.
J Urol ; 134(1): 199-202, 1985 Jul.
Article in English | MEDLINE | ID: mdl-3892047

ABSTRACT

To obtain objective data on deletion of the ABH isoantigens in bladder carcinoma, microfluorometry was used. Slides were scanned in phase contrast to lessen fading of the immuno- or lectin-fluorescence stained cells. The fluorescence intensity was measured in relation to an external uranyl standard. Staining was most intense in the peripheral and cytoplasmic parts of the cells. The intra specimen fluorescence intensity varied as 1 to 10. In nondeleted cell populations fluorescence intensity means ranged from 1025 to 12,550 and in deleted populations from 304 to 510. Microfluorometry accurately separates deleted cell populations from those with a normal ABH antigen content.


Subject(s)
ABO Blood-Group System/immunology , Carcinoma in Situ/immunology , Carcinoma, Transitional Cell/immunology , Urinary Bladder Neoplasms/immunology , Carcinoma in Situ/pathology , Carcinoma, Transitional Cell/pathology , Flow Cytometry , Fluorescent Antibody Technique , Humans , Therapeutic Irrigation , Urinary Bladder Neoplasms/pathology
16.
Urology ; 25(4): 361-2, 1985 Apr.
Article in English | MEDLINE | ID: mdl-3984122

ABSTRACT

Treatment of postoperative urine leakage after a lower pole resection by embolic occlusions of segmental arteries using pure ethanol in a thirty-four-year-old man is described. There were no postoperative complications, and follow-up examination at two years showed a functioning but small kidney in a patient without symptoms.


Subject(s)
Embolization, Therapeutic , Ethanol , Kidney Diseases/therapy , Renal Artery Obstruction/chemically induced , Adult , Humans , Kidney Calices/physiopathology , Kidney Diseases/etiology , Kidney Diseases/physiopathology , Male , Postoperative Complications
17.
Urol Res ; 13(2): 43-5, 1985.
Article in English | MEDLINE | ID: mdl-3892840

ABSTRACT

Fluorescence methods for determining ABH isoantigens on transitional cells were developed for the study of cytologic material. Indirect immunofluorescence was used for A- and B-antigens, fluorescein-labeled Ulex Europaeus lectin for the H-antigen. Isoantigens of 151 patients with bladder carcinoma were studied. Patients with a malignant cytology showed deletion in 31/65 cases compared to 12/62 cases when the cytology was benign. Cyto-flow ploidy determinations were abnormal in 41/120 cases measured; cells from 21 of these 41 had isoantigen deletion compared to 25/79 cases with a diploid pattern. The ABH isoantigen deletion shows some relation to malignant cytology, abnormal ploidy and a visible tumor, but is probably an independent parameter.


Subject(s)
ABO Blood-Group System , Carcinoma/analysis , Isoantigens/analysis , Urinary Bladder Neoplasms/analysis , Carcinoma/blood , Female , Fluorescent Antibody Technique , Humans , Male , Urinary Bladder Neoplasms/blood
18.
Urol Res ; 13(5): 219-21, 1985.
Article in English | MEDLINE | ID: mdl-4060365

ABSTRACT

The tissue concentrations of a modified nucleoside, pseudouridine, and a normal nucleoside, uridine, were measured with high-performance liquid chromatography. Human kidneys were obtained from five patients with renal cell carcinoma and divided into a noncancerous part and a cancerous part. The pseudouridine concentration in the cancerous part of the kidneys ranged between less than 2-2.8 nmoles/g and in the noncancerous part 4.3-19.4 nmoles/g (mean 10,9 nmoles/g). The uridine concentration in the cancerous and noncancerous parts of the kidney ranged between 19.6-179.1 nmoles/g (mean 110.7 nmoles/g) and 117.5-235.6 nmoles/g (mean 191.5 nmoles/g), respectively. The pseudouridine concentration appeared to be approximately seven times higher in the noncancerous part as compared to the cancerous part of the kidney. In the case of uridine, the difference was less pronounced.


Subject(s)
Kidney Neoplasms/metabolism , Kidney/metabolism , Pseudouridine/metabolism , Uridine/analogs & derivatives , Uridine/metabolism , Carcinoma, Renal Cell/metabolism , Chromatography, High Pressure Liquid , Humans , Tissue Distribution
19.
Urol Res ; 13(5): 213-8, 1985.
Article in English | MEDLINE | ID: mdl-4060364

ABSTRACT

Using a sensitive and specific method involving high-performance liquid chromatography, urinary levels of four modified nucleosides--pseudouridine (psi), 1-methylinosine (m1I), 1-methyladenosine (m1A), and 1-methylguanosine (m1G)--were investigated before and after treatment in 31 patients with cancer of the urinary organs or the female genital tract. Before treatment m1I was the most frequently elevated nucleoside (77%). Pretreatment urinary levels of psi, m1I, and m1A in patients with stage 2-4 cancer of the female genital tract were significantly elevated compared to human healthy volunteers (p less than 0.005). Compared with the other nucleosides, psi appeared to correlate more closely with the clinical outcome (progression or regression) of patients with cancer of the female genital tract. In the case of patients with cancer of the urinary organs, m1I followed the clinical outcome better than the other nucleosides measured. Therefore psi and m1I seem to be useful for monitoring genito-urinary cancers.


Subject(s)
Nucleosides/urine , Urogenital Neoplasms/urine , Adenosine/analogs & derivatives , Adenosine/urine , Adult , Carcinoma, Renal Cell/therapy , Carcinoma, Renal Cell/urine , Female , Genital Neoplasms, Female/therapy , Genital Neoplasms, Female/urine , Guanosine/analogs & derivatives , Guanosine/urine , Humans , Inosine/analogs & derivatives , Inosine/urine , Kidney Neoplasms/therapy , Kidney Neoplasms/urine , Pseudouridine/urine , Urinary Bladder Neoplasms/therapy , Urinary Bladder Neoplasms/urine , Urogenital Neoplasms/therapy
20.
Arch Orthop Trauma Surg (1978) ; 99(3): 175-81, 1982.
Article in English | MEDLINE | ID: mdl-6978698

ABSTRACT

The use of prophylactic antibiotics was studied prospectively in 2371 consecutive clean orthopedic operations. The infection rates for operations with obvious selection for antibiotic prophylaxis were twice as high (7.2%) as compared with operations with planned prophylaxis (3.4%) and with operations without such prophylaxis (3.7%). Sixteen per cent of all clean operations received antibiotics for prophylaxis and 85 per cent of all prophylactic courses lasted at least 8 days or longer. Fifty-one per cent of all antimicrobial drugs used during the study were administered for prophylaxis in clean orthopaedic operations. The length of the hospital stay was the only factor closely related to the length of antibiotic prophylaxis. The drugs most often used for prophylaxis were penicillinase-resistent penicillins. Significant increase of gram-negative pathogens was observed in cultures from wounds of patients on antibiotic prophylaxis.


Subject(s)
Orthopedics , Penicillins/therapeutic use , Premedication , Surgical Wound Infection/prevention & control , Humans , Penicillinase/metabolism , Penicillins/administration & dosage , Surgical Wound Infection/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...